不孕女性中子宫腺肌病的患病率:系统综述与Meta分析
该系统综述与Meta分析检索了截至2022年10月的多个数据库,纳入21项纵向研究共25600名不孕女性,发现孤立性子宫腺肌病的合并患病率为10%(95%CI 6-15%),合并子宫肌瘤时为1%,合并子宫内膜异位症时为6%,合并子宫内膜异位症和/或肌瘤时为7%。
要点
- 不孕女性中孤立性子宫腺肌病的合并患病率为10%(95%CI 6-15%)。
- 合并子宫肌瘤时患病率为1%,合并子宫内膜异位症时为6%,合并子宫内膜异位症和/或肌瘤时为7%。
- 澳大利亚的孤立性子宫腺肌病合并患病率最高(19%),显著高于亚洲(5%)。
核心结论
- 不孕女性中每10人约有1人诊断为孤立性子宫腺肌病,其患病率随合并子宫内膜异位症和/或子宫肌瘤的存在而变化。
研究设计与样本
- 系统检索MEDLINE、EMBASE、CINAHL Plus、Google Scholar、PsycINFO和Web of Science Core Collection,从建库至2022年10月,纳入评估不孕女性中子宫腺肌病患病率的研究,共21项纵向研究、25600名女性。
主要发现
- 孤立性子宫腺肌病的总体合并患病率为10%(95%CI 6-15%),异质性I²=99.1%,tau²=0.12。
- 合并子宫肌瘤的子宫腺肌病合并患病率为1%(95%CI 0-4%),共8项研究,I²=95.8%,tau²=0.03。
- 合并子宫内膜异位症的子宫腺肌病合并患病率为6%(95%CI 3-11%),共18项研究,I²=98.6%,tau²=0.12。
- 合并子宫内膜异位症和/或子宫肌瘤的子宫腺肌病合并患病率为7%(95%CI 2-13%),共9项研究,I²=98.3%,tau²=0.09。
- 澳大利亚的孤立性子宫腺肌病合并患病率最高,为19%(95%CI 12-27%),显著高于亚洲的5%(95%CI 1-12%)。
关键数值与推荐
- 采用直接和间接超声特征联合诊断时,孤立性子宫腺肌病合并患病率为11%(95%CI 7-16%);仅以间接特征作为诊断标准的研究中为0.45%(95%CI 0-1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the prevalence of adenomyosis in women with subfertility. METHODS: A systematic search was conducted in MEDLINE, EMBASE, CINAHL Plus, Google Scholar, PsycINFO and Web of Science Core Collection from database inception to October 2022. The included studies evaluated the prevalence of adenomyosis in women with subfertility, with or without endometriosis and/or uterine fibroids. Secondary analyses were conducted to identify variation in the prevalence of isolated adenomyosis according to geographical location, diagnostic modality, diagnostic criteria, type of ultrasound, ultrasound features of adenomyosis and the use of assisted reproductive technology. RESULTS: Among 21 longitudinal studies evaluating 25 600 women, the overall pooled prevalence of isolated adenomyosis was 10% (95% CI, 6-15%) (I2 = 99.1%; tau2 = 0.12). The pooled prevalence was 1% (95% CI, 0-4%) for adenomyosis with concurrent fibroids (eight studies; I2 = 95.8%; tau2 = 0.03), 6% (95% CI, 3-11%) for adenomyosis with concurrent endometriosis (18 studies; I2 = 98.6%; tau2 = 0.12) and 7% (95% CI, 2-13%) for adenomyosis with concurrent endometriosis and/or fibroids (nine studies; I2 = 98.3%; tau2 = 0.09). The prevalence of isolated adenomyosis varied substantially according to geographical location, with Australia exhibiting the highest pooled prevalence of adenomyosis (19% (95% CI, 12-27%)), which was significantly higher compared with that in Asia (5% (95% CI, 1-12%)). The pooled prevalence of isolated adenomyosis diagnosed using a combination of direct and indirect ultrasound features was 11% (95% CI, 7-16%), whereas it was 0.45% (95% CI, 0-1%) in the study in which only an indirect feature was used as the diagnostic criterion. CONCLUSION: One in 10 women with subfertility have a diagnosis of isolated adenomyosis. The prevalence of adenomyosis varies according to the presence of concurrent endometriosis and/or fibroids. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Mishra I, Melo P, Easter C, et al. Prevalence of adenomyosis in women with subfertility: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2023. PMID: 36647238. doi:10.1002/uog.26159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。